Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy

ConclusionsThese findings suggest that IDO expression is a mechanism of immune evasion used by prostate cancer and that future clinical trials using T-cell-based immune strategies might best include IDO inhibition.

Source: Cancer Immunology, Immunotherapy - October 11, 2019 Category: Cancer & Oncology Source Type: research